<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111058</article-id><article-id pub-id-type="publisher-id">ACM-40161</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_53919747.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血液净化在多发性骨髓瘤肾病中的应用
  Application of Blood Purification in Multiple Myeloma Nephropathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>应丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>永萍</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>大理大学临床医学院，云南 大理</addr-line></aff><aff id="aff3"><addr-line>大理大学第一附属医院，云南 大理</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>410</fpage><lpage>416</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    多发性骨髓瘤为常见的血液系统恶性肿瘤，肾脏损害是其最常见和严重的并发症之一，体外血液净化治疗可以有效地清除多发性骨髓瘤患者体内过多的游离轻链，从而改善患者肾功能及预后。本文就多发性骨髓瘤肾病的血液净化方式进行讨论总结。
    Multiple myeloma (MM) is a common hematological malignancy. Renal injury is one of the most common and serious complications. Extracorporeal blood purification therapy can effectively remove the excessive free light chain in patients with MM, thus improving the renal function and prognosis of patients. In this paper, the blood purification methods of MM nephropathy are discussed and summarized. 
  
 
</p></abstract><kwd-group><kwd>多发性骨髓瘤肾病，血液净化，游离轻链，预后, Multiple Myeloma Nephropathy</kwd><kwd> Blood Purification</kwd><kwd> Free Light Chain</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>多发性骨髓瘤为常见的血液系统恶性肿瘤，肾脏损害是其最常见和严重的并发症之一，体外血液净化治疗可以有效地清除多发性骨髓瘤患者体内过多的游离轻链，从而改善患者肾功能及预后。本文就多发性骨髓瘤肾病的血液净化方式进行讨论总结。</p></sec><sec id="s2"><title>关键词</title><p>多发性骨髓瘤肾病，血液净化，游离轻链，预后</p></sec><sec id="s3"><title>Application of Blood Purification in Multiple Myeloma Nephropathy<sup> </sup></title><p>Yingli Yang<sup>1</sup>, Yongping Li<sup>2</sup></p><p><sup>1</sup>Department of Clinical Medicine, Dali University, Dali Yunnan</p><p><sup>2</sup>First Affiliated Hospital of Dali University, Dali Yunnan</p><p><img src="//html.hanspub.org/file/58-1571858x4_hanspub.png" /></p><p>Received: Dec. 28<sup>th</sup>, 2020; accepted: Jan. 21<sup>st</sup>, 2021; published: Jan. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/58-1571858x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Multiple myeloma (MM) is a common hematological malignancy. Renal injury is one of the most common and serious complications. Extracorporeal blood purification therapy can effectively remove the excessive free light chain in patients with MM, thus improving the renal function and prognosis of patients. In this paper, the blood purification methods of MM nephropathy are discussed and summarized.</p><p>Keywords:Multiple Myeloma Nephropathy, Blood Purification, Free Light Chain, Prognosis</p><disp-formula id="hanspub.40161-formula43"><graphic xlink:href="//html.hanspub.org/file/58-1571858x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/58-1571858x7_hanspub.png" /> <img src="//html.hanspub.org/file/58-1571858x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>多发性骨髓瘤(Multiple myeloma, MM)是一种恶性浆细胞疾病，约占血液系统恶性肿瘤的13%，占所有恶性肿瘤的1% [<xref ref-type="bibr" rid="hanspub.40161-ref1">1</xref>]。MM患者临床表现复杂，常累及多个脏器，肾损害是MM最常见和严重的并发症之一。由MM引起的肾功能不全又被称为骨髓瘤相关肾脏疾病(Myeloma associated kidney disease, MRKD)，发生在15%~40%的MM患者中 [<xref ref-type="bibr" rid="hanspub.40161-ref2">2</xref>]。MRKD最常见的病理学类型是管型肾病，其产生机制主要是：血中单克隆免疫球蛋白游离轻链(Free immunoglobulin light chains, FLCs)对近端肾小管的直接毒性，以及超过近曲小管重吸收能力而被转运至远曲小管的过多游离轻链蛋白与Tamm-Horsfall蛋白结合形成蛋白管型导致远端肾小管阻塞，最终造成肾小管间质纤维化 [<xref ref-type="bibr" rid="hanspub.40161-ref3">3</xref>]。若肾损害发展为终末期肾病则需血液净化治疗。血液净化(blood purification)即把患者血液引出体外，通过净化装置去除血液中的一些致病物质，从而达到治疗疾病的过程，它全面概括了血液透析、血液滤过、血液透析滤过、血液灌流、血浆置换和免疫吸附等现有的各种血液净化技术 [<xref ref-type="bibr" rid="hanspub.40161-ref4">4</xref>]。研究表明，MM伴有肾功能损害并依赖透析的患者预后较差，死亡率达到67% [<xref ref-type="bibr" rid="hanspub.40161-ref5">5</xref>]。合适的血液净化治疗不仅能够清除MM患者体内的尿素氮、血肌酐以及使患者内环境稳定，而且能够清除MM患者体内过多的FLCs，从而促进肾功能恢复 [<xref ref-type="bibr" rid="hanspub.40161-ref6">6</xref>]。</p></sec><sec id="s6"><title>2. 普通血液透析</title><p>普通血液透析(Conventional hemodialysis, conv.HD)截留的分子质量在500以下，理论上无法清除MRKD患者血中过多的FLCs。Gerald C等提出，在普通血液透析过程中，存在两种不同对抗机制影响轻链水平：血液透析本身似乎导致轻链在血浆中的出现率增加，轻链水平低的时候这一效应最为明显，这一现象的机制尚不清楚；在轻链水平较高时，普通血液透析在使用聚甲基丙烯酸甲酯(Polymethyl methacrylate, PMMA)膜时，可以通过吸附和透析去除FLCs，并认为PMMA膜对FLCs的去除主要是吸附 [<xref ref-type="bibr" rid="hanspub.40161-ref7">7</xref>]。Fabbrini P等在2013年发现PMMA膜可以吸附血清κ型和λ型FLCs，对λ型的吸附效果尤为显著，即使λ型FLCs浓度大于4000 mg/l，每次普通血液透析治疗(历时4小时)可实现40%或更大的FLCs降低，但是对于κ型FLCs的吸附作用远远低于λ型FLCs，主要的原因可能是由于κ型的基础浓度明显高于λ型FLCs，而这导致了透析器纤维的快速饱和 [<xref ref-type="bibr" rid="hanspub.40161-ref8">8</xref>]。总之，目前可用的普通血液透析无法使包括MRKD在内的终末期肾病患者升高的血浆FLCs水平正常化。</p></sec><sec id="s7"><title>3. 血浆置换</title><p>自1960年Schwab和Fahey第一次对巨球蛋白血症患者进行治疗性的血浆置换以降低患者的高球蛋白水平开始，血浆置换逐渐在许多疾病的治疗中发挥优势 [<xref ref-type="bibr" rid="hanspub.40161-ref9">9</xref>]。血浆置换(Plasma exchange, PE)即将患者血液引出体外，利用血浆分离器将血浆和细胞成分分离，从而去除致病性血浆或只选择性去除血浆中的某些致病大分子物质，再将净化后的血浆、补充的置换液输回体内的一种血液净化方法 [<xref ref-type="bibr" rid="hanspub.40161-ref4">4</xref>]，尤其对那些难以通过药物及机体自身代谢的致病物质有快速去除作用。MM患者体内过多的IgA、IgD、IgG (相对分子质量150,000)也可由血浆置换去除。目前认为血浆置换对MRKD有效的主要原因是PE可以从血清中直接体外去除FLCs。然而，由于血清FLC的半衰期短，仅有15%~20%在血管内分布 [<xref ref-type="bibr" rid="hanspub.40161-ref10">10</xref>]，因此理论上，单次PE治疗仅能清除少部分FLC，也就是说PE受到治疗反弹的限制。Zucchelli P等人早期对29例MM伴急性肾衰竭患者进行研究发现，PE联合化疗组和单纯化疗组患者的生存率和肾功能恢复率无差异 [<xref ref-type="bibr" rid="hanspub.40161-ref11">11</xref>]。1998年至2003年间进行的最大的一项随机对照试验，招募了MM伴严重急性肾功能损伤患者，结果未能显示出PE对患者和肾脏结果的有益影响，此研究的局限性还包括缺乏肾活检证实骨髓瘤管型肾病的诊断以及缺乏血清或尿轻链的定量 [<xref ref-type="bibr" rid="hanspub.40161-ref12">12</xref>]，这也是PE在MM肾损害治疗中存在争议的原因。但是Burnette BL等提出在MM伴管型肾病中，PE联合硼替佐米治疗可以有效地逆转急性肾功能衰竭 [<xref ref-type="bibr" rid="hanspub.40161-ref13">13</xref>]。因此PE可能使临床表现为急性肾损伤、尿白蛋白排泄量较低、血清游离轻链 &gt; 200 mg/dL [<xref ref-type="bibr" rid="hanspub.40161-ref13">13</xref>] 的高度怀疑或通过病理证实为管型肾病的MM患者获益。2007年美国血浆置换学会制定的血浆置换适应证中(ASFA 2007)，认为在骨髓瘤伴急性肾衰竭、多发性骨髓瘤(IgA/IgD/IgM型)中，血浆置换提示有效，但有益证据不明确，在有效性或风险/效益比上证据不足；当传统疗法没有产生满意的疗效或作为经机构审查委员会批准的研究方案的一部分时，可以应用血浆分离置换治疗 [<xref ref-type="bibr" rid="hanspub.40161-ref14">14</xref>]。而且PE本身就有增加总住院费用和延长住院时间的独立风险 [<xref ref-type="bibr" rid="hanspub.40161-ref15">15</xref>]。因此，如果没有正式的比较研究，PE应用于MM伴肾损害的有效性仍然值得怀疑，未来还需要进一步严格设计的随机对照研究来证实。</p></sec><sec id="s8"><title>4. 免疫吸附</title><p>吸附是血液净化清除溶质的一个重要原理 [<xref ref-type="bibr" rid="hanspub.40161-ref4">4</xref>]，免疫吸附(Immunoadsorption, IA)，也称为血浆吸附，即先分离血浆，再将具有高度特异性的抗原、抗体或具有特定理化亲和力的物质与吸附材料结合制成吸附柱，使其中相应的致病因子可以选择性或特异性地被吸附 [<xref ref-type="bibr" rid="hanspub.40161-ref4">4</xref>]。Ray P.K等人报道了将金黄色葡萄球菌Cowan I悬液作为免疫吸附剂的体外免疫吸附可以去除MM患者(IgG型)的IgG分子 [<xref ref-type="bibr" rid="hanspub.40161-ref16">16</xref>]。国内罗乐宣等人1988年第一次将IA应用于MM并肾功能衰竭患者，用蛋白A免疫吸附清除MM患者血浆中升高的免疫球蛋白，IgG、IgA、IgM分别从25.37 g/L、1.61 g/L、1.67 g/L下降至4.43 g/L、0.51 g/L、0.31 g/L，清除率分别为82.5%、68.3%和81.4%，治疗后患者肾功能逐渐恢复，最终脱离透析 [<xref ref-type="bibr" rid="hanspub.40161-ref17">17</xref>]。虽然免疫吸附用于治疗免疫介导性疾病已有几十年历史，且认为与PE相比，IA具有高特异性和选择性、对血浆成分影响小、处理血浆量大、无需补充血浆制品和外源性感染机会极微的优越性 [<xref ref-type="bibr" rid="hanspub.40161-ref17">17</xref>]；但在MM伴肾损害的治疗中仍缺乏数据的支持，随着吸附柱提高及“智能膜”的开发，IA可能未来能为MM患者带来福音。</p></sec><sec id="s9"><title>5. 高通量血液透析</title><p>高通量透析，即使用具有由疏水性膜制成、尿素的透析器溶质转运系数(KoA)高及超滤系数 &gt; 20 ml/(h∙mmHg∙m<sup>2</sup>)透析器的透析 [<xref ref-type="bibr" rid="hanspub.40161-ref4">4</xref>]。从截留的相对分子质量角度又可以将高通量透析分为普通高通量透析(截留相对分子质量 &lt; 20,000)、中截血液透析(Medium cut-off hemodialysis, MCO，截留相对分子质量20,000~60,000)和高截血液透析(High cut-off hemodialysis, HCO，截留相对分子质量 &gt; 60,000) [<xref ref-type="bibr" rid="hanspub.40161-ref18">18</xref>]。虽然目前还缺乏标准化的定义，但是习惯性将中截量血液透析与高截量血液透析(High cut-off hemodialysis, HCO-HD)统称为超高通血液透析(super high flux hemodialysis) [<xref ref-type="bibr" rid="hanspub.40161-ref18">18</xref>]。</p><sec id="s9_1"><title>5.1. 普通高通量血液透析</title><p>普通高通量血液透析截留的分子量一般为15,000~20,000，且膜生物相容性好。理论上高通量血液透析不能清除游离轻链蛋白，但是近年来的一些研究提出普通高通量血液透析能清除MM急性肾损伤患者的FLCs。2011年Granger Vallee A等通过构建动力学模型对17个采用普通高通量血液透析的MM伴肾衰竭需要进行肾脏替代治疗的患者进行了回顾性分析，结果发现普通高通量血液透析对κ型和λ型FLCs的清除速率分别达到33.8 ml/min和19.7 ml/min [<xref ref-type="bibr" rid="hanspub.40161-ref19">19</xref>]。2014年Lamy T等人通过对31名由不同原因引起肾功能衰竭的慢性肾脏病5期患者进行分析，发现经过1次普通高通量血液透析治疗后，患者的κ型FLCs和λ型FLCs分别由透析前87 &#177; 27 mg/L、72 &#177; 41 mg/L，降至透析后47 &#177; 27 mg/L、53 &#177; 31 mg/L，β<sub>2</sub>微球蛋白也由透析前30 &#177; 7 mg/L下降至透析后11 &#177; 2 mg/L [<xref ref-type="bibr" rid="hanspub.40161-ref20">20</xref>]。虽说研究对象并非MM伴肾功能衰竭患者，但同样给了我们启示，普通高通量血液透析治疗能使终末期肾脏病患者血浆中的FLCs及β2微球蛋白显著下降。随后，Bourguignon C 等在2015年进行了一项针对MM伴慢性肾脏病5期病人的小型前瞻性研究，发现通过4个月的规律普通高通量血液透析治疗(每周3次，每次3~4小时)，患者的血清κ型和λ型轻链蛋白分别下降了65.5%和36.6%，κ/λ比值达到0.8，而κ/λ比值在0.26~1.65之间是肾功能正常受试者所描述的参考范围 [<xref ref-type="bibr" rid="hanspub.40161-ref21">21</xref>]。Gerth HU等通过对17例MM合并急性肾损伤患者进行至少每周3次，每次平均时间为240分钟的普通高通量血液透析治疗，30天后有5名(29.4%)患者肾功能恢复 [<xref ref-type="bibr" rid="hanspub.40161-ref22">22</xref>]。2017年Bridoux F报道了48例以硼替佐米为基础治疗的采用普通高通量血液透析的MM患者，3个月室脱离透析率为33.3% (16例)，且随着透析时间延长，脱离透析的可能性有所增加，到12月时，脱离透析的患者数量达到18例(37.5%) [<xref ref-type="bibr" rid="hanspub.40161-ref23">23</xref>]。总之，普通高通量血液透析能在一定程度上降低MM伴肾损害患者的FLCs水平，基于此，可以在一定程度上改善患者的预后，但目前的相关研究中所涉及的患者数量小，未来仍需要大规模的前瞻性试验证实。</p></sec><sec id="s9_2"><title>5.2. 高截留量血液透析</title><p>2012年，Hutchison Colin A等人报道了67例继发于MM的透析依赖性肾功能衰竭患者在化疗基础上进行了HCO-HD治疗，平均接受了12次(3~45次) HCO-HD治疗，其中42例(63%)在经过平均11.5次HCO-HD治疗后脱离透析 [<xref ref-type="bibr" rid="hanspub.40161-ref24">24</xref>]。Curti Adriano等在2016年对19例MM伴管型肾病的肾衰竭患者进行了回顾性分析，其中12例采用了HCO-HD治疗，7例采用了普通HD治疗，最终提出：进行HCO-HD治疗的患者与常规透析的患者相比，具有更好的生存和更快、更好的肾脏恢复的趋势 [<xref ref-type="bibr" rid="hanspub.40161-ref25">25</xref>]，同时提出HCO-HD治疗组患者的生存和肾脏恢复均与血清FLCs降低程度显著相关。但是，HCO-HD在不化疗的情况下去除FLCs的益处有限，因为在未化疗的MM患者中，单克隆FLCs的产生率很高，Hutchison CA等也提出，持续降低血清FLC浓度需要有效的化疗 [<xref ref-type="bibr" rid="hanspub.40161-ref26">26</xref>]。同时，也建议应用HCO-HD清除FLCs的治疗时，可以延长治疗时间(每次透析时间 &gt; 4小时)，这样将允许FLCs重新分配，从而能够增加FLCs的清除 [<xref ref-type="bibr" rid="hanspub.40161-ref27">27</xref>]。HCO-HD透析膜的孔径较大，所以透析过程中大量白蛋白丢失，同时HCO-HD治疗造成更大经济负担；所以目前认为，在严格的条件下，可能建议在透析依赖性管型肾病患者中使用HCO-HD治疗，但不建议长期应用。为了得出明确的结论，需要进行前瞻性对照试验 [<xref ref-type="bibr" rid="hanspub.40161-ref25">25</xref>]。由此，两项随机对照试验EuLITE和MYRE正在进行中，然而，由于MM并透析依赖的罕见发生率，患者招募可能将会耗费许多时间 [<xref ref-type="bibr" rid="hanspub.40161-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.40161-ref27">27</xref>]。</p></sec></sec><sec id="s10"><title>6. 血液滤过</title><p>血液滤过(hemofiltration)是在超滤技术基础上发展起来的，对溶质的清除模拟肾小球的滤过作用，即以对流转运的方式进行清除，因为模仿了生物肾的工作原理，所以血滤最大的特点为血流动力学稳定 [<xref ref-type="bibr" rid="hanspub.40161-ref4">4</xref>]。2012年Mehta等人对MM伴肾功能衰竭需要透析的3名患者进行了报道，3名患者经过连续5天(每天至少18小时)连续静脉血液滤过治疗(Continuous veno-venous hemofiltration, CVVH)，患者的肾功能均有好转，联合化疗及自体干细胞移植治疗后患者均脱离透析，Mehta等还对其中两名患者的κ型FLCs的清除率进行了测量，分别为30和20 ml/分钟 [<xref ref-type="bibr" rid="hanspub.40161-ref28">28</xref>]。国内咸伟2013年对40名MM伴有慢性肾功能衰竭患者进行了前瞻性研究，将患者随机分为单纯化疗组20例与CVVH联合化疗组20例，最终肾功能恢复正常者有16例(40%)，其中CVVH与联合化疗组占10例(62.5%)，且治疗后轻链蛋白、血钙、血尿酸均显著地优于单纯化疗组，具有统计学意义(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.40161-ref29">29</xref>]。总之，血液滤过能以对流转运的方式进行对FLCs进行清除，但因缓慢的血流量限制了FLCs的清除速率，以及凝血发生率较高和透析时间长以致患者难以接受等限制了其在MM伴肾功能衰竭患者中的应用。</p></sec><sec id="s11"><title>7. 血液透析滤过</title><p>血液透析滤过(Hemodiafiltration, HDF)即通过弥散高效地清除小分子物质和通过对流高效清除中分子物的一种血液透析技术 [<xref ref-type="bibr" rid="hanspub.40161-ref4">4</xref>]。1978年Bosch J.P第一次将血液透析滤过应用于临床且对尿毒症毒素的清除取得短时高效的效果，短短几十年中，HDF的临床应用越来越广泛 [<xref ref-type="bibr" rid="hanspub.40161-ref30">30</xref>]。Midori Hasegawa等在2010年对一例IgG-λ型MM伴急性肾衰竭患者进行了报道，其肾活检提示管型肾病伴中度间质纤维化和肾小管萎缩，即使采用了不同透析器，经过规律的HDF后，患者的血清λ型FLCs清除率均达到60%以上，清除速率为10.5~28.8 ml/分钟，在此基础上联合化疗，患者最终脱离透析 [<xref ref-type="bibr" rid="hanspub.40161-ref31">31</xref>]。Bourguignon C等在2015年的一项研究对比了普通高通量血液透析与血液透析滤过在清除FLCs的差异，提出HDF较普通高通量血液透析具有优越性 [<xref ref-type="bibr" rid="hanspub.40161-ref21">21</xref>]，对患者的血清κ型和λ型轻链蛋白均具有清除效果，且清除效果随着HDF治疗时间延长而加强 [<xref ref-type="bibr" rid="hanspub.40161-ref21">21</xref>]。Li Cavoli G等人在2017年对3例依赖血液透析的MM患者进行了报道，经过HDF治疗后，FLCs的分别降低了32.2%、33.4%和49.5% [<xref ref-type="bibr" rid="hanspub.40161-ref32">32</xref>]。虽然在不同研究中，HDF对FLCs的清除率有所不同，但HDF对FLCs具有良好的清除效率是毋庸置疑的，且可以避免大量白蛋白的丢失，MM伴肾衰竭患者有望从中获益。</p></sec><sec id="s12"><title>8. 结语</title><p>多发性骨髓瘤合并肾功能衰竭一旦发生就意味着较差的预后，对于这类患者来说，合适的血液净化治疗无疑能够及时、有效地清除患者FLCs等毒素，从而促进肾功能恢复以及改善患者预后。在MM伴肾损伤患者中，普通血液透析虽能清除尿素氮、肌酐等小分子物质，但对FLCs的清除作用有限，故并不推荐应用；血浆置换对FLCs的清除有效，但对预后的有益证据不明确，且增加患者住院费用，应谨慎选择；免疫吸附可以通过吸附清除FLCs，但目前缺乏前瞻性试验来证实IA对MM伴肾损伤患者的预后是否有益；不管是普通高通量血液透析还是高截留量血液透析对FLCs均有明显的清除作用，联合化疗能改善部分患者的预后，但目前研究均为小样本研究，仍需要前瞻性、多中心的大型临床试验来证实；血液滤过可以清除FLCs，但清除速率低、凝血发生率高和透析时间长限制其应用；血液透析滤过对FLCs具有良好的清除作用，且目前的部分研究认为HDF对MM伴肾损伤患者的治疗效果优于普通高通量血液透析。综上所述，不同的血液净化方式均可以清除MM伴肾损伤患者的部分FLCs，目前普遍认为高通量血液透析和血液透析滤过对FLCs清除效果更佳，但相关研究大多为小样本回顾性研究，仍需要更多的证据证实其作用。因此，在MM伴肾损害患者血液净化方式的选择上，临床医师需要结合患者的临床特点和经济状况进行谨慎选择。</p></sec><sec id="s13"><title>基金项目</title><p>云南省临床医学中心分中心开发项目(2019LCZXKF-07)。</p></sec><sec id="s14"><title>文章引用</title><p>杨应丽,李永萍. 血液净化在多发性骨髓瘤肾病中的应用Application of Blood Purification in Multiple Myeloma Nephropathy[J]. 临床医学进展, 2021, 11(01): 410-416. https://doi.org/10.12677/ACM.2021.111058</p></sec><sec id="s15"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40161-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Moreau, P., Attal, M. and Facon, T. (2015) Frontline Therapy of Multiple Myeloma. Blood, 125, 3076-3084. 
&lt;br&gt;https://doi.org/10.1182/blood-2014-09-568915</mixed-citation></ref><ref id="hanspub.40161-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., et al. (2003) Review of 1027 Patients with Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 78, 21-33. &lt;br&gt;https://doi.org/10.4065/78.1.21</mixed-citation></ref><ref id="hanspub.40161-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Herrera, G.A. and Sanders, P.W. (2007) Paraproteinemic Renal Diseases That Involve the Tubule-Interstitium. Contributions to Nephrology, 153, 105-115. &lt;br&gt;https://doi.org/10.1159/000096763</mixed-citation></ref><ref id="hanspub.40161-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">王质刚. 血液净化学[M]. 北京: 北京科学技术出版社, 2010.</mixed-citation></ref><ref id="hanspub.40161-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Decourt, A., Gondouin, B., Delaroziere, J.C., Brunet, P., Sallée, M., Burtey, S., et al. (2016) Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. Clinical Journal of the American Society of Nephrology, 11, 431-441. &lt;br&gt;https://doi.org/10.2215/CJN.06290615</mixed-citation></ref><ref id="hanspub.40161-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dimopoulos, M.A., Roussou, M., Gavriatopoulou, M., Psimenou, E., Eleutherakis-Papaiakovou, E., Migkou, M., et al. (2016) Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. American Journal of Hematology, 91, 499-502. &lt;br&gt;https://doi.org/10.1002/ajh.24335</mixed-citation></ref><ref id="hanspub.40161-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, G., Rudnicki, M., Schmaldienst, S. and Hörl, W.H. (2002) Effect of Dialysis on Serum/Plasma Levels of Free Immunoglobulinlight Chains in End-Stage Renal Disease Patients. Nephrology Dialysis Transplantation, 17, 879-883. 
&lt;br&gt;https://doi.org/10.1093/ndt/17.5.879</mixed-citation></ref><ref id="hanspub.40161-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Fabbrini, P., Sirtori, S., Casiraghi, E., Pieruzzi, F., Genovesi, S., Corti, D., et al. (2013) Polymethylmethacrylate Membrane and Serum Free Light Chain Removal: Enhancing Adsorption Properties. Blood Purification, 35, 52-58. 
&lt;br&gt;https://doi.org/10.1159/000350849</mixed-citation></ref><ref id="hanspub.40161-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Schwab, P.J. and Fahey, J.L. (1960) Treatment of Waldenstrom’s Macroglobulinemia by Plasmapheresis. The New England Journal of Medicine, 263, 574-579. &lt;br&gt;https://doi.org/10.1056/NEJM196009222631202</mixed-citation></ref><ref id="hanspub.40161-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Takagi, K., Kin, K., Itoh, Y., Enomoto, H. and Kawai, T. (1980) Human Alpha1-Microglobulin Levels in Various Body Fluids. Journal of Clinical Pathology, 3, 786-791. http://dx.doi.org/10.1136/jcp.33.8.786</mixed-citation></ref><ref id="hanspub.40161-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zucchelli, P., Pasquali, S., Cagnoli, L. and Ferrari, G. (1988) Controlled Plasma Exchange Trial in Acute Renal Failure Due to Multiple Myeloma. Kidney International, 33, 1175-1180. &lt;br&gt;https://doi.org/10.1038/ki.1988.127</mixed-citation></ref><ref id="hanspub.40161-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Clark, W.F., Stewart, A.K., Rock, G.A., Sternbach, M., Sutton, D.M., Barrett, B.J., Heidenheim, A.P., Garg, A.X. and Churchill, D.N. (2005) Canadian Apheresis Group: Plasma Exchange When Myeloma Presents as Acute Renal Failure: A Randomized, Controlled Trial. Annals of Internal Medicine, 143, 777-784.  
&lt;br&gt;https://doi.org/10.7326/0003-4819-143-11-200512060-00005</mixed-citation></ref><ref id="hanspub.40161-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Burnette, B.L., Leung, N. and Rajkumar, S.V. (2011) Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange. The New England Journal of Medicine, 364, 2365-2366. 
&lt;br&gt;https://doi.org/10.1056/NEJMc1101834</mixed-citation></ref><ref id="hanspub.40161-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Szczepiorkowski, Z.M., Bandarenko, N., Kim, H.C., Kim, H.C., Linenberger, M.L., Marques, M.B., et al. (2007) Guidelines on the Use of Therapeutic Apheresis in Clinical Practice: Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. Journal of Clinical Apheresis, 22, 106-175.</mixed-citation></ref><ref id="hanspub.40161-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Dhakal, B., Miller, S., Rein, L., Pathak, L.K., Gloria, L., Szabo, A., et al. (2020) Trends in the Use of Therapeutic Plasma Exchange in Multiple Myeloma. Journal of Clinical Apheresis, 35, 307-315.</mixed-citation></ref><ref id="hanspub.40161-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ray, P.K., Besa, E., Idiculla, A., Rhoads, J.E., Bassett, J.G. and Cooper, D.R. (1980) Extracorporeal Immunoadsorption of Myeloma IgG and Autoimmune Antibodies: A Clinically Feasible Modality of Treatment. Clinical and Experimental Immunology, 42, 308-314.</mixed-citation></ref><ref id="hanspub.40161-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">罗乐宣, 于宗周. 免疫吸附治疗多发性骨髓瘤伴肾功能衰竭初探[J]. 中华肾脏病杂志, 1998(3): 181.</mixed-citation></ref><ref id="hanspub.40161-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">卢方平. 超高通量(中-高截)血液透析的研究进展[J]. 中国血液净化, 2017, 16(4): 270-272. 
http://dx.chinadoi.cn/10.3969/j.issn.1671-4091.2017.04.014</mixed-citation></ref><ref id="hanspub.40161-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Vallée Alexandre, G., Leila, C., Hélène, L.-M., Laure, P., Chantal, C., Guillaume, C., Jean-Paul, C. and Bernard, C. (2011) Online High-Efficiency Haemodiafiltration Achieves Higher Serum Free Light Chain Removal than High-Flux haemodialysis in Multiple Myeloma Patients: Preliminary Quantitative Study. Nephrology, Dialysis, Transplantation, 26, 3627-3633. &lt;br&gt;https://doi.org/10.1093/ndt/gfr180</mixed-citation></ref><ref id="hanspub.40161-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lamy, T., Henri, P., Lobbedez, T., Comby, E., Ryckelynck, J.-P., Ficheux, M., et al. (2014) Comparison between on-Line High-Efficiency Hemodiafiltration and Conventional High-Flux Hemodialysis for Polyclonal Free Light Chain Removal. Blood Purification, 37, 93-98. &lt;br&gt;https://doi.org/10.1159/000357968</mixed-citation></ref><ref id="hanspub.40161-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Bourguignon, C., Chenine, L., Bargnoux, A.S., Leray-Moragues, H., Canaud, B., Cristol, J.P. and Morena, M. (2016) Hemodiafiltration Improves Free Light Chain Removal and Normalizes κ/λ Ratio in Hemodialysis Patients. Journal of Nephrolog, 29, 251-257. &lt;br&gt;https://doi.org/10.1007/s40620-015-0207-z</mixed-citation></ref><ref id="hanspub.40161-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Gerth, H.U., Pohlen, Mi., Görlich, D., Thölking, G., Kropff, M., Beel, W.E., Pavenstädt, H., Brand, M. and Kümpers, P. (2016) Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. PLoS One, 115, e0154993. &lt;br&gt;https://doi.org/10.1371/journal.pone.0154993</mixed-citation></ref><ref id="hanspub.40161-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Bridoux, F., Carron, P.L., Pegourie, B., Alamartine, E., Augeul-Meunier, K., Karras, A., Joly, B., Peraldi, M.N., Arnulf, B., Vigneau, C., Lamy, T., Wynckel, A., Kolb, B., Royer, B., Rabot, N., Benboubker, L., Combe, C., Jaccard, A., Moulin, B., Knebelmann, B., Chevret, S. and Fermand, J.P. (2017) Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence among Patients with Myeloma Cast Nephropathy: A Randomized Clinical Trial. JAMA, 318, 2099-2110. &lt;br&gt;https://doi.org/10.1001/jama.2017.17924</mixed-citation></ref><ref id="hanspub.40161-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Hutchison, C.A., Heyne, N., Airia, P., Schindler, R., Zickler, D., Cook, M., Cockwell, P. and Grima, D. (2012) Immunoglobulin Free Light Chain Levels and Recovery from Myeloma Kidney on Treatment with Chemotherapy and High Cut-Off Haemodialysis. Nephrology, Dialysis, Transplantation, 27, 3823-3828. &lt;br&gt;https://doi.org/10.1093/ndt/gfr773</mixed-citation></ref><ref id="hanspub.40161-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Adriano, C., Albin, S., Johannes, T., Yuki, T. and Ambühl, P.M. (2016) Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy. PLoS ONE, 11, e0159942. &lt;br&gt;https://doi.org/10.1371/journal.pone.0159942</mixed-citation></ref><ref id="hanspub.40161-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Hutchison, C.A., Bradwell, A.R., Cook, M., Basnayake, K., Basu, S., Harding, S., et al. (2009) Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis. Clinical Journal of the American Society of Nephrology, 4, 745-54. &lt;br&gt;https://doi.org/10.2215/CJN.04590908</mixed-citation></ref><ref id="hanspub.40161-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Hutchison, C.A., Cook, M., Heyne, N., Weisel, K., Billingham, L., Bradwell, A., et al. (2008) European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy (EuLITE): A Randomised Control Trial. Trials, 9, Article No. 55. &lt;br&gt;https://doi.org/10.1186/1745-6215-9-55</mixed-citation></ref><ref id="hanspub.40161-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mehta, S., Shtaynberg, N., Goldman, M., et al. (2012) Use of Continuous Venovenous Hemofiltration for Acute Renal Failure Due to Multiple Myeloma Cast Nephropathy. Hematology, 17, 229-231.  
&lt;br&gt;https://doi.org/10.1179/1607845412Y.0000000003</mixed-citation></ref><ref id="hanspub.40161-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">咸伟, 申捷, 王素娟, 祁云香, 罗志尚. 多发性骨髓瘤肾病并发慢性肾功能衰竭行连续性血液滤过的治疗观察[J]. 中国医药科学, 2013, 3(17): 69-71.</mixed-citation></ref><ref id="hanspub.40161-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Bosch, J.P., Geronemus, R., Glabman, S., Lysaght, M., Kahn, T. and von Albertini, B. (1978) High Flux Hemofiltration. Artificial organs, 2, 339-342. &lt;br&gt;https://doi.org/10.1111/j.1525-1594.1978.tb01617.x</mixed-citation></ref><ref id="hanspub.40161-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Hasegawa, M., Kondo, F., Yamamoto, K., Murakami, K., Tomita, M., Nabeshima, K., Nakai, S., Kato, M., Ohashi, A., Arai, J., Hiki, Y., Ishii, J., Emi, N., Sugiyama, S. and Yuzawa, Y. (2010) Evaluation of Blood Purification and Bortezomib Plus Dexamethasone Therapy for the Treatment of Acute Renal Failure Due to Myeloma Cast Nephropathy. Therapeutic Apheresis and Dialysis, 14, 451-456. &lt;br&gt;https://doi.org/10.1111/j.1744-9987.2010.00863.x</mixed-citation></ref><ref id="hanspub.40161-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Li Cavoli, G., Passanante, S., Schillaci, O., Servillo, F., Zagarrigo, C., Li Cavoli, T.V., et al. (2017) Haemodiafiltration with Ultrafiltrate Regeneration in the Removal of Free Light Chains in Multiple Myeloma and Acute Kidney Injury. Nefrologia, 38, 337-338. &lt;br&gt;https://doi.org/10.1016/j.nefro.2017.06.007</mixed-citation></ref></ref-list></back></article>